The price of Constellium shares is range-bound. This phase will end sooner or later when volatility comes back. Investors have an opportunity to buy the stock and target the $ 13.7.
The company has solid fundamentals for a short-term investment strategy.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.54 for the 2018 fiscal year.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 8.59 USD
Stock prices approach a strong long-term resistance in weekly data at USD 13.1.
The group shows a rather high level of debt in proportion to its EBITDA.
The company's earnings releases usually do not meet expectations.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.